Antibody-mediated signaling through PD-1 costimulates T cells and enhances CD28-dependent proliferation

被引:24
作者
del Rio, ML
Penuelas-Rivas, G
Dominguez-Perles, R
Ramirez, P
Parrilla, P
Rodriguez-Barbosa, JI [1 ]
机构
[1] Arrixaca Univ Hosp, Unit Transplantat Res, Murcia 30120, Spain
[2] Arrixaca Univ Hosp, Dept Surg, Liver Transplant Unit, Murcia 30120, Spain
关键词
costimulation; programmed death-1 (PD-1CD279); T cell proliferation;
D O I
10.1002/eji.200535232
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Programmed death-1 (PD-1, CD279) is a molecule expressed on activated T, B and myeloid cells. The role of the interaction of PD-1 ligands (PD-L1 and PD-L2) with PD-1 receptor and the type of signals (costimulatory or inhibitory) that are delivered is a subject of intense debate. Our study has characterized two monoclonal antibodies (mAb) against murine PD-1, termed clone 1H10 and clone 4F10, that recognized different epitopes from that of anti-PD-1, clone J43. We showed that neither of them inhibited anti-CD3-mediated proliferation, but 1H10 mAb induced direct T cell proliferation in the absence of any other stimulus. Moreover, PD-1 engagement with 1H10 mAb costimulated anti-CD3-mediated proliferation and enhanced anti-CD3/CD28 proliferation on both CD4(+) and CD8(+) T cells in the low range of anti-CD3 concentrations. Anti-PD-1-mediated proliferation induced with 1H10 mAb was also observed in vivo on CD4(+) and CD8(+) T cells, when CFSE-labeled splenocytes were adoptively transferred to irradiated syngeneic and allogeneic recipients. Overall, our data indicate that PD-1 might not only deliver negative signals to T cells upon interaction through one of its ligands, PD-L1 as reported, but also could costimulate T cells, suggesting a dual potential functional activity of the extracellular domains of this receptor.
引用
收藏
页码:3545 / 3560
页数:16
相关论文
共 51 条
[1]   Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes [J].
Agata, Y ;
Kawasaki, A ;
Nishimura, H ;
Ishida, Y ;
Tsubata, T ;
Yagita, H ;
Honjo, T .
INTERNATIONAL IMMUNOLOGY, 1996, 8 (05) :765-772
[2]   The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice [J].
Ansari, MJI ;
Salama, AD ;
Chitnis, T ;
Smith, RN ;
Yagita, H ;
Akiba, H ;
Yamazaki, T ;
Azuma, M ;
Iwai, H ;
Khoury, SJ ;
Auchincloss, H ;
Sayegh, MH .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (01) :63-69
[3]   CD4+ T cell division in irradiated mice requires peptides distinct from those responsible for thymic selection [J].
Bender, J ;
Mitchell, T ;
Kappler, J ;
Marrack, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (03) :367-373
[4]   THE ANTIGENIC STRUCTURE OF PROTEINS - A REAPPRAISAL [J].
BENJAMIN, DC ;
BERZOFSKY, JA ;
EAST, IJ ;
GURD, FRN ;
HANNUM, C ;
LEACH, SJ ;
MARGOLIASH, E ;
MICHAEL, JG ;
MILLER, A ;
PRAGER, EM ;
REICHLIN, M ;
SERCARZ, EE ;
SMITHGILL, SJ ;
TODD, PE ;
WILSON, AC .
ANNUAL REVIEW OF IMMUNOLOGY, 1984, 2 :67-101
[5]   Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-γ-dependent mechanism [J].
Blazar, BR ;
Carreno, BM ;
Panoskaltsis-Mortari, A ;
Carter, L ;
Iwai, Y ;
Yagita, H ;
Nishimura, H ;
Taylor, PA .
JOURNAL OF IMMUNOLOGY, 2003, 171 (03) :1272-1277
[6]   Blockade of programmed death-1 Ligands on dendritic cells enhances T cell activation and cytokine production [J].
Brown, JA ;
Dorfman, DM ;
Ma, FR ;
Sullivan, EL ;
Munoz, O ;
Wood, CR ;
Greenfield, EA ;
Freeman, GJ .
JOURNAL OF IMMUNOLOGY, 2003, 170 (03) :1257-1266
[7]  
Brunner MC, 1999, J IMMUNOL, V162, P5813
[8]   BTLA: a new inhibitory receptor with a B7-like ligand [J].
Carreno, BM ;
Collins, M .
TRENDS IN IMMUNOLOGY, 2003, 24 (10) :524-527
[9]   The B7 family of ligands and its receptors: New pathways for costimulation and inhibition of immune responses [J].
Carreno, BM ;
Collins, M .
ANNUAL REVIEW OF IMMUNOLOGY, 2002, 20 :29-53
[10]  
Carter LL, 2002, EUR J IMMUNOL, V32, P634, DOI 10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO